Letynol (Cefotaxime Sodium Sterile)

Cefotaxime sodium exerts its antibacterial effect by binding to penicillin‑binding proteins located on the bacterial cell wall. This binding blocks the transpeptidation step of peptidoglycan synthesis, weakening the wall and causing osmotic lysis of the bacterium. The result is a rapid, bactericidal action against a wide range of susceptible pathogens.

The dosage of Letynol is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and the chosen route of administration (intravenous or intramuscular). Because dosing varies widely across indications, the prescriber determines the appropriate regimen and duration for each patient.

Safety data for cefotaxime in pregnancy are limited, and the drug is generally classified as Category B or C depending on the jurisdiction. It should be used only if the potential benefit justifies any potential risk to the fetus. Limited information exists for lactating mothers; a risk‑benefit assessment by the prescriber is required before use.

To request Letynol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and assist with any required import documentation.

Both Letynol (cefotaxime) and ceftriaxone belong to the third‑generation cephalosporin class, but they differ in pharmacokinetics. Cefotaxime has a shorter half‑life, requiring more frequent dosing (every 6–8 hours), whereas ceftriaxone’s longer half‑life allows once‑daily dosing. Cefotaxime is often preferred for severe meningitis due to better cerebrospinal fluid penetration, while ceftriaxone is convenient for outpatient therapy.

Letynol must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. It should not be frozen or shaken. After reconstitution, the solution should be used within the time frame specified in the product label, typically within 24 hours if kept refrigerated.

Letynol is supplied as a sterile powder for solution and is administered by a qualified health professional either as an intravenous infusion or an intramuscular injection. The preparation involves reconstituting the powder with a suitable diluent, followed by administration according to the prescribed rate and volume.

The most serious adverse reactions associated with Letynol include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, neutropenia or agranulocytosis, acute renal impairment, and seizures, particularly in patients with pre‑existing central nervous system disorders.

Patients with a documented hypersensitivity to cefotaxime, other cephalosporins, or any β‑lactam antibiotics should not receive Letynol. Caution is also advised for individuals with severe renal impairment, as dose adjustment is required, and for those with a history of severe allergic reactions to related antibiotics.